Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.

Expert opinion on therapeutic patents - 1 Mar 2024

Reichl Kyle D, Lee Esther C Y, Gopalsamy Ariamala

Abstract excerpt

INTRODUCTION: The multi-subunit SWI/SNF chromatin remodeling complex is a key epigenetic regulator for many cellular processes, and several subunits are found to be mutated in human cancers. The inactivating mutations of SMARCA4, the ATPase subunit of the complex, result in cellular dependency on the paralog SMARCA2 for survival. This observed synthetic lethal relationship posits targeting SMARCA2 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphatases
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Helicases

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Nuclear Proteins

Share to Patents as Topic

Share to Synthetic Lethal Mutations

Source

Identifiers

PMID: 38578210
DOI: 10.1080/13543776.2024.2338111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.PMID 38578210Read ↗

Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 2023Semantic proximity Read ↗

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.Semantic proximity Read ↗

The role of SMARCA4 in lung cancerSemantic proximity Read ↗

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C InhibitorsSemantic proximity Read ↗

[Research Progress on SMARCA4 Mutation Non-small Cell Lung Cancer].Semantic proximity Read ↗

Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.Semantic proximity Read ↗

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.Semantic proximity Read ↗

A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.Semantic proximity Read ↗

Gene of the month: <i>SMARCB1</i>Semantic proximity Read ↗

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersSemantic proximity Read ↗

Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.Semantic proximity Read ↗

Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.